دورية أكاديمية
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
| العنوان: | Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma |
|---|---|
| المؤلفون: | Hess, Georg, Dreyling, Martin, Oberic, Lucie, Gine, Eva, Zinzani, Pier Luigi, Linton, Kim, Vilmar, Adam, Jerkeman, Mats, Chen, Jenny M.H., Ohler, Anke, Stilgenbauer, Stephan, Thieblemont, Catherine, Lambert, Jonathan, Zilioli, Vittorio Ruggero, Sancho, Juan Manuel, Jimenez-Ubieto, Ana, Fischer, Luca, Eyre, Toby A., Keeping, Sam, Park, Julie E., Wu, James J., Nunes, Ana, Reitan, John, Wade, Sally W., Salles, Gilles |
| المصدر: | Leukemia and Lymphoma; (2023) ; ISSN: 1042-8194 |
| بيانات النشر: | Taylor & Francis |
| سنة النشر: | 2023 |
| المجموعة: | Lund University Publications (LUP) |
| مصطلحات موضوعية: | Hematology, brexucabtagene autoleucel, CAR T-cell therapy, indirect treatment comparison, mantle cell lymphoma, non-Hodgkin lymphoma, standard of care |
| الوصف: | The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://lup.lub.lu.se/record/e5ec2026-68b4-45f8-9b07-27a18b131ec3Test; http://dx.doi.org/10.1080/10428194.2023.2268228Test; scopus:85174242231; pmid:37840282 |
| DOI: | 10.1080/10428194.2023.2268228 |
| الإتاحة: | https://doi.org/10.1080/10428194.2023.2268228Test https://lup.lub.lu.se/record/e5ec2026-68b4-45f8-9b07-27a18b131ec3Test |
| رقم الانضمام: | edsbas.7FD56730 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1080/10428194.2023.2268228 |
|---|